57 related articles for article (PubMed ID: 38755218)
1. Immune profiling of dedifferentiated liposarcoma and identification of novel antigens for targeted immunotherapy.
Jirovec A; Flaman A; Godbout E; Serrano D; Werier J; Purgina B; Diallo JS
Sci Rep; 2024 May; 14(1):11254. PubMed ID: 38755218
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma.
Kelly CM; Qin LX; Whiting KA; Richards AL; Avutu V; Chan JE; Chi P; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Adamson T; Singer S; Bartlett EK; Crago AM; Yoon SS; Hwang S; Erinjeri JP; Antonescu CR; Tap WD; D'Angelo SP
Clin Cancer Res; 2023 Jun; 29(11):2043-2051. PubMed ID: 36971773
[TBL] [Abstract][Full Text] [Related]
3. Vanadium exposure exacerbates allergic airway inflammation and remodeling through triggering reactive oxidative stress.
Tu W; Xiao X; Lu J; Liu X; Wang E; Yuan R; Wan R; Shen Y; Xu D; Yang P; Gong M; Gao P; Huang SK
Front Immunol; 2022; 13():1099509. PubMed ID: 36776398
[TBL] [Abstract][Full Text] [Related]
4. The immune landscape of undifferentiated pleomorphic sarcoma.
Lazcano R; Barreto CM; Salazar R; Carapeto F; Traweek RS; Leung CH; Gite S; Mehta J; Ingram DR; Wani KM; Vu KT; Parra ER; Lu W; Zhou J; Witt RG; Cope B; Thirasastr P; Lin HY; Scally CP; Conley AP; Ratan R; Livingston JA; Zarzour AM; Ludwig J; Araujo D; Ravi V; Patel S; Benjamin R; Wargo J; Wistuba II; Somaiah N; Roland CL; Keung EZ; Solis L; Wang WL; Lazar AJ; Nassif EF
Front Oncol; 2022; 12():1008484. PubMed ID: 36313661
[TBL] [Abstract][Full Text] [Related]
5. The immune subtypes and landscape of sarcomas.
Weng W; Yu L; Li Z; Tan C; Lv J; Lao IW; Hu W; Deng Z; Liu Z; Wang J; Xu M
BMC Immunol; 2022 Sep; 23(1):46. PubMed ID: 36153483
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immunotherapy in the Management of Soft Tissue Sarcomas: Current Landscape and Future Outlook.
Banks LB; D'Angelo SP
J Natl Compr Canc Netw; 2022 Jul; 20(7):834-844. PubMed ID: 35830892
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Italiano A; Bessede A; Pulido M; Bompas E; Piperno-Neumann S; Chevreau C; Penel N; Bertucci F; Toulmonde M; Bellera C; Guegan JP; Rey C; Sautès-Fridman C; Bougoüin A; Cantarel C; Kind M; Spalato M; Dadone-Montaudie B; Le Loarer F; Blay JY; Fridman WH
Nat Med; 2022 Jun; 28(6):1199-1206. PubMed ID: 35618839
[TBL] [Abstract][Full Text] [Related]
8. Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis.
Tu Z; Peng J; Long X; Li J; Wu L; Huang K; Zhu X
Front Immunol; 2022; 13():844736. PubMed ID: 35592314
[TBL] [Abstract][Full Text] [Related]
9. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.
Thirasastr P; Somaiah N
Ther Adv Med Oncol; 2022; 14():17588359221081073. PubMed ID: 35251319
[TBL] [Abstract][Full Text] [Related]
10. PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
Lee DH; Jeong YJ; Won JY; Sim HI; Park Y; Jin HS
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203508
[TBL] [Abstract][Full Text] [Related]
11. Hallmarks of Cancer: New Dimensions.
Hanahan D
Cancer Discov; 2022 Jan; 12(1):31-46. PubMed ID: 35022204
[TBL] [Abstract][Full Text] [Related]
12. Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma.
Livingston MB; Jagosky MH; Robinson MM; Ahrens WA; Benbow JH; Farhangfar CJ; Foureau DM; Maxwell DM; Baldrige EA; Begic X; Symanowski JT; Steuerwald NM; Anderson CJ; Patt JC; Kneisl JS; Kim ES
Clin Cancer Res; 2021 Dec; 27(23):6424-6431. PubMed ID: 34475102
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
Schroeder BA; LaFranzo NA; LaFleur BJ; Gittelman RM; Vignali M; Zhang S; Flanagan KC; Rytlewski J; Riolobos L; Schulte BC; Kim TS; Chen E; Smythe KS; Wagner MJ; Mantilla JG; Campbell JS; Pierce RH; Jones RL; Cranmer LD; Pollack SM
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34465597
[TBL] [Abstract][Full Text] [Related]
14. Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives.
Nishio J; Nakayama S; Nabeshima K; Yamamoto T
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362013
[TBL] [Abstract][Full Text] [Related]
15. Conventional Treatments Cannot Improve Outcomes of Early-Stage Primary Breast Marginal Zone Lymphoma.
Liu H; Zhang J; Quan L; Cao L; Miao Y; Zhao X; Shen H; Wang L; Xu W; Li J; Fan L
Front Oncol; 2020; 10():609512. PubMed ID: 33928019
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
Tang K; Wu YH; Song Y; Yu B
J Hematol Oncol; 2021 Apr; 14(1):68. PubMed ID: 33883013
[TBL] [Abstract][Full Text] [Related]
17. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.
Somaiah N; Chawla SP; Block MS; Morris JC; Do K; Kim JW; Druta M; Sankhala KK; Hwu P; Jones RL; Gnjatic S; Kim-Schulze S; Tuballes K; Yishak M; Lu H; Yakovich A; Ter Meulen J; Chen M; Kenney RT; Bohac C; Pollack SM
Oncoimmunology; 2020 Nov; 9(1):1847846. PubMed ID: 33312760
[TBL] [Abstract][Full Text] [Related]
18. VCAM1 Promotes Tumor Cell Invasion and Metastasis by Inducing EMT and Transendothelial Migration in Colorectal Cancer.
Zhang D; Bi J; Liang Q; Wang S; Zhang L; Han F; Li S; Qiu B; Fan X; Chen W; Jiao H; Ye Y; Ding Y
Front Oncol; 2020; 10():1066. PubMed ID: 32793471
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
